Skip to content
10-Q

Quarterly Report

CNBX PHARMACEUTICALS INC. CNBX

0001683168-25-000267

← back to feed
Filed
Jan 13, 2025 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q1 2025 · Jan 12, 2025 31.11M sh
Cash And Equivalents Q1 2025 · Nov 30, 2024 $17.34K
Cash And Equivalents Q1 2025 · Aug 31, 2024 $26.42K
Current Liabilities Q1 2025 · Nov 30, 2024 $2.54M
Current Liabilities Q1 2025 · Aug 31, 2024 $2.51M
Current Assets Q1 2025 · Nov 30, 2024 $22.31K
Current Assets Q1 2025 · Aug 31, 2024 $31.39K
Total Assets Q1 2025 · Nov 30, 2024 $22.31K
Total Assets Q1 2025 · Aug 31, 2024 $31.39K
Shares Diluted Q1 2025 · Nov 30, 2023 27.76M sh
Operating Cash Flow Q1 2025 · Nov 30, 2023 −$71.85K
Stockholders Equity Q1 2025 · Nov 30, 2023 −$2.09M
Stockholders Equity Q1 2025 · Aug 31, 2023 −$2.02M
Eps Diluted restated Q1 2025 · Nov 30, 2023 −$0.01
Eps Basic restated Q1 2025 · Nov 30, 2023 −$0.01
Sga Expense Q1 2025 · Nov 30, 2023 $148.92K
Rd Expense Q1 2025 · Nov 30, 2023 $112.42K
Net Income Q1 2025 · Nov 30, 2023 −$178.52K
Operating Income Q1 2025 · Nov 30, 2023 −$171.9K
Revenue Q1 2025 · Nov 30, 2023 $89.44K